Evidence map›Paper›PMID 42170006›Full record

ArticleInternational journal of nanomedicine2026

Tromethamine‑Modified Chlorambucil Prodrug Nano-Micelles: Improved Colloidal Stability and Antitumor Efficacy.

Zhifang Li, Shengheng Xu, Xuelian Jiang, Xue Yang, Shaoheng Cui, Yuchao Lu, Xiao Duan, Jinping Zheng

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhifang Li *Changzhi Key Laboratory of Drug Molecular Design and Innovative Pharmaceutics, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, 046000, People's Republic of China.
Shengheng Xu *Changzhi Key Laboratory of Drug Molecular Design and Innovative Pharmaceutics, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, 046000, People's Republic of China.
Xuelian Jiang *Changzhi Key Laboratory of Drug Molecular Design and Innovative Pharmaceutics, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, 046000, People's Republic of China.
Xue YangChangzhi Key Laboratory of Drug Molecular Design and Innovative Pharmaceutics, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, 046000, People's Republic of China.
Shaoheng CuiShanxi Provincial Department-Municipal Key Laboratory Cultivation Base for Quality Enhancement and Utilization of Shangdang Chinese Medicinal Materials, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, 046000, People's Republic of China.
Yuchao LuChangzhi Key Laboratory of Drug Molecular Design and Innovative Pharmaceutics, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, 046000, People's Republic of China.
Xiao DuanChangzhi Key Laboratory of Drug Molecular Design and Innovative Pharmaceutics, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, 046000, People's Republic of China.
Jinping ZhengShanxi Key Laboratory of Aging Mechanism Research and Translational Applications, Changzhi Medical College, Changzhi, Shanxi, 046000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chlorambucil ( Methods: An amphiphilic prodrug ( Results: Conclusion: This carrier-minimized prodrug platform concurrently overcomes the solubility, stability, and toxicity bottlenecks of nitrogen mustard chemotherapy, offering a simple and translatable strategy for enhancing the clinical efficacy of chlorambucil.

Indexed as

Antineoplastic AgentsChlorambucilNanoparticlesProdrugsAnimalsAntineoplastic Agents, AlkylatingApoptosisCell Line, TumorCell SurvivalColloidsDrug StabilityFemaleHumansMiceMicellesAntineoplastic AgentsAntineoplastic Agents, AlkylatingChlorambucilColloidsMicellesProdrugscancer therapychlorambucilnanomicellesprodrugtromethamine

Identifiers

PMID42170006
PMCPMC13189193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.